Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma Biotech Investing
U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine Biotech Investing
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon Pharmaceutical Investing
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer Pharmaceutical Investing
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application for KEYTRUDA® in High-Risk Early-Stage Triple-Negative Breast Cancer Pharmaceutical Investing
DEADLINE ALERT for PLUG, NEPT, BLU, RIDE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders Biotech Investing
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma Biotech Investing
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29 Pharmaceutical Investing
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness
